BridgePort Financial Solutions LLC Purchases 50 Shares of Vertex Pharmaceuticals Incorporated $VRTX

BridgePort Financial Solutions LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 843 shares of the pharmaceutical company’s stock after buying an additional 50 shares during the period. BridgePort Financial Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $375,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in VRTX. Activest Wealth Management bought a new position in Vertex Pharmaceuticals during the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd grew its stake in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 45 shares in the last quarter. Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at $32,000. American National Bank & Trust lifted its position in shares of Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 67 shares in the last quarter. Finally, SJS Investment Consulting Inc. grew its position in shares of Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

VRTX has been the topic of a number of recent research reports. Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Saturday, September 27th. Guggenheim decreased their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Finally, HC Wainwright lowered their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $493.81.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $403.30 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The stock’s 50 day simple moving average is $399.12 and its two-hundred day simple moving average is $442.50. The stock has a market cap of $103.40 billion, a price-to-earnings ratio of 28.83 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.